Beijing, China

Yanshen Kang

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):

Title: Yanshen Kang: Innovator in Therapeutic Antibodies

Introduction

Yanshen Kang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of immunology through his innovative work on therapeutic antibodies. With a total of 2 patents, his research focuses on advancing cancer treatment and diagnostics.

Latest Patents

Yanshen Kang's latest patents include the development of Anti-PD-L1 antibodies and their use as therapeutics and diagnostics. These antibodies specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells. The patents detail antibodies that bind to a set of amino acid residues required for ligand binding, with applications in treating or diagnosing cancer, infectious diseases, or other pathological disorders modulated by PD-L1-mediated functions.

Career Highlights

Yanshen Kang is associated with Beigene, Ltd., a leading biotechnology company focused on developing innovative medicines for cancer treatment. His work has been instrumental in advancing therapeutic options for patients.

Collaborations

Some of Yanshen Kang's notable coworkers include Kang Li and Jing Song, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Yanshen Kang's contributions to the field of therapeutic antibodies highlight his role as an innovator in medical science. His work continues to pave the way for advancements in cancer treatment and diagnostics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…